Cargando…

The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization

BACKGROUND AND PURPOSE: Molecular profiling should be performed on all advanced non-small cell lung cancer with non-squamous histology to allow treatment selection. Currently, this should include EGFR mutation testing and testing for ALK rearrangements. ROS1 is another emerging target. ALK rearrange...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tembuyser, Lien, Tack, Véronique, Zwaenepoel, Karen, Pauwels, Patrick, Miller, Keith, Bubendorf, Lukas, Kerr, Keith, Schuuring, Ed, Thunnissen, Erik, Dequeker, Elisabeth M. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227804/ https://www.ncbi.nlm.nih.gov/pubmed/25386659 http://dx.doi.org/10.1371/journal.pone.0112159

Ejemplares similares

A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer
por: Keppens, Cleo, et al.
Publicado: (2018)

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
por: Thunnissen, Erik, et al.
Publicado: (2012)

Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
por: Keppens, Cleo, et al.
Publicado: (2020)

Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories
por: Tack, Véronique, et al.
Publicado: (2018)

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres
por: Boleij, Annemarie, et al.
Publicado: (2016)

Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?
por: Keppens, Cleo, et al.
Publicado: (2019)

Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers
por: Keppens, Cleo, et al.
Publicado: (2020)

Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys
por: Keppens, Cleo, et al.
Publicado: (2020)

Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?
por: Hiddinga, Birgitta, et al.
Publicado: (2022)

Testing for ROS1 in non-small cell lung cancer: a review with recommendations
por: Bubendorf, Lukas, et al.
Publicado: (2016)

Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders
por: Dufraing, Kelly, et al.
Publicado: (2022)

Results of a worldwide external quality assessment of cfDNA testing in lung Cancer
por: Fairley, Jennifer A., et al.
Publicado: (2022)

International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA
por: Keppens, Cleo, et al.
Publicado: (2018)

Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
por: Masood, Ashiq, et al.
Publicado: (2021)

Structure of AlkB–AlkG shows details of alkane terminal C–H selectivity and functionalization
Publicado: (2023)

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza
por: Bubendorf, Lukas, et al.
Publicado: (2017)

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL
por: Dufraing, K., et al.
Publicado: (2020)

Guidance for laboratories performing molecular pathology for cancer patients
por: Cree, Ian A, et al.
Publicado: (2014)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

Patient- and Family-centered Rounding: A Single-site Look into the Room
por: Rubin, Alexandra, et al.
Publicado: (2021)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
por: Wei, Jiacong, et al.
Publicado: (2018)

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group
por: Dietel, Manfred, et al.
Publicado: (2016)

Analysis of Micro-Machining Process for External Thread of Micro Round Tube
por: Chen, Tsung-Chia, et al.
Publicado: (2021)

The Significance of External Quality Assessment Schemes for Molecular Testing in Clinical Laboratories
por: Laudus, Nele, et al.
Publicado: (2022)

ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex
por: Williams, Eleanor, et al.
Publicado: (2021)

Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
por: Gielen, F., et al.
Publicado: (1976)

The potential environmental impact of external speakers’ airplane travel to grand rounds conferences
por: Monahan, Sally, et al.
Publicado: (2023)

External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different
por: Dodson, Andrew, et al.
Publicado: (2019)

Assessing Relevance of External Cognitive Measures
por: Cairó, Osvaldo
Publicado: (2017)

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey
por: Deans, Zandra C., et al.
Publicado: (2017)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

RhoA is required for cortical retraction and rigidity during mitotic cell rounding
por: Maddox, Amy Shaub, et al.
Publicado: (2003)

Gargamelle in the West Area - control room for the external electronic detectors
Publicado: (1977)

Purely Organic Microparticles Showing Ultralong Room Temperature Phosphorescence
por: Thomas, Heidi, et al.
Publicado: (2021)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

Future Challenges in Nocturia: Relevance to Voiding Clock?
por: Lee, Tack
Publicado: (2011)

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing
por: Patton, S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_35ad9lqm38p9m6mo7nkoqj95uu